Medvi vs Ro Health for GLP-1 Weight Loss (2026)

Medvi and Ro Health both operate as cash-pay GLP-1 telehealth programs — no insurance required, direct-to-patient prescribing. Medvi entered the market with aggressive pricing on compounded medications; Ro has established itself as a multi-medication, full-service telehealth platform. For patients comparing these two options, the key questions are price, medication access, and provider depth.

---

Quick Comparison

	Medvi	Ro Health
Monthly cost	~$99–149/month	~$149–199/month
Semaglutide access	Compounded semaglutide	Compounded + brand-name
Tirzepatide access	Compounded tirzepatide	Compounded + brand-name
Brand-name GLP-1	Limited	Yes (Wegovy, Zepbound through Ro pharmacy)
Prescriber type	Nurse practitioners / physicians	Physicians and NPs
Ongoing doctor visits	Async check-ins	Async + scheduled video
Coaching / behavioral support	Limited	Yes — weight loss coaching included
Lab review	On request	Included in program
Insurance navigation	No	No (cash-pay focused)

---

Medvi: Low-Cost Entry into Compounded GLP-1

Medvi positions itself as the lowest-friction, lowest-cost path to compounded semaglutide and tirzepatide. The intake process is primarily online questionnaire-based; prescribers review asynchronously; medications ship directly.

Medvi strengths:

• Among the lowest pricing in cash-pay GLP-1 telehealth (~$99–149/month)
• Straightforward intake and approval process
• Tirzepatide access at compounded pricing (~$149–199/month)
• No long-term commitment — monthly billing

Medvi limitations:

• Less clinical depth than established platforms
• Coaching and behavioral support is minimal
• Reactive rather than proactive provider communication
• No direct access to brand-name GLP-1 if compounding is restricted
• Newer platform with less track record than competitors

---

Ro Health: Established Full-Service Platform

Ro launched one of the first large-scale GLP-1 telehealth programs and has built infrastructure around weight loss care: prescribing, a pharmacy network, behavioral coaching, and lab services. Ro's weight loss program (Body) operates as an integrated program rather than just prescription access.

Ro strengths:

• Established platform with larger patient volume and iteration history
• Access to brand-name Wegovy/Zepbound if insurance coverage is obtained
• Weight loss coaching included (structured behavioral support)
• Scheduled video visits with providers (not just async)
• Lab panel review as part of intake and monitoring
• Compounded semaglutide and tirzepatide also available as cash-pay option

Ro limitations:

• Higher cost than Medvi (~$149–199/month for compounded; more for brand-name pathways)
• Primarily a cash-pay platform — no serious insurance navigation
• Scheduling can be slow for video visits

---

Pricing Comparison

Option	Medvi	Ro
Compounded semaglutide	~$99–149/month	~$149/month
Compounded tirzepatide	~$149–199/month	~$149–199/month
Brand-name Wegovy	Not primary offering	Through Ro pharmacy (varies; ~$350–500/month after Novo coupons)
Annual estimate (compounded)	~$1,188–1,788	~$1,788–2,388

The price differential at compounded semaglutide (~$50/month savings with Medvi) adds up to ~$600/year — meaningful but not transformative.

---

Who Each Program Serves Best

Medvi is better if you:

• Want the lowest possible monthly cost for compounded GLP-1
• Don't need structured behavioral support or coaching
• Are comfortable with mostly asynchronous provider communication
• Have already been on GLP-1 and know how to manage your treatment
• Want a simple, no-frills prescription + medication delivery service

Ro is better if you:

• Want coaching, behavioral support, and a more integrated experience
• Value scheduled video visits with providers rather than async-only
• Want the option of brand-name medication access if your situation changes
• Are new to GLP-1 and want more clinical hand-holding
• Want lab review included in the program

---

The Compounding Regulatory Risk

Both Medvi and Ro offer compounded semaglutide and tirzepatide — which are less expensive than brand-name medications but subject to FDA regulatory changes. The FDA declared semaglutide shortage resolved in late 2024 and tirzepatide shortage resolved in 2025, putting compounding pharmacies in a legally ambiguous position under 503A/503B frameworks.

Both providers pivoted to comply; patients should understand that:

• Compounded pricing depends on ongoing pharmacy network access
• Brand-name access is more stable long-term but significantly more expensive
• Ro's brand-name pathway provides a fallback that Medvi does not prominently offer

---

Related Resources

• Medvi Weight Loss Review — full program review
• Ro Health Review — full program review
• Ro vs Henry Meds GLP-1 — Ro vs another low-cost option
• Compounded vs Brand-Name GLP-1 — safety, legality, pricing differences
• Best Cash-Pay GLP-1 Programs — full ranking of affordable options